Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
EDITORIAL

Why a special issue on anal cancer and what is in it?

Christopher K. Fairley A B F , Julia M. L. Brotherton B C , Richard Hillman D and Andrew E. Grulich E

A Melbourne Sexual Health Centre, Alfred Health, Melbourne, Vic. 3053, Australia.

B School of Population Health, University of Melbourne, Melbourne, Vic. 3010, Australia.

C Victorian Cytology Service, East Melbourne, Vic. 8002, Australia.

D Western Sydney Sexual Health Centre, University of Sydney, 162 Marsden Street, Parramatta, NSW 2150, Australia.

E Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.

F Corresponding author. Email: cfairley@mshc.org.au

Sexual Health 9(6) 501-503 http://dx.doi.org/10.1071/SH12109
Submitted: 10 July 2012  Accepted: 3 September 2012   Published: 27 November 2012

Abstract

This editorial describes the contents of this special issue of Sexual Health devoted to anal cancer. The aim of the issue is to provide readers with information to assist them in making decisions about what to do about detecting anal cancer early in men who have sex with men with HIV. Should they be advocating screening? It discusses the epidemiology of HPV infection, anal intraepithelial neoplasia, and anal cancer in MSM, heterosexual men and women; anal cancer screening and treatment of anal cancer. And most importantly, what should be done about vaccinating boys with the HPV vaccine.


References

[1]  Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. Sex Health 2012; 9 504–8.
| 22958581PubMed | open url image1

[2]  Machalek DA, et al Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13 487–500.
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis.CrossRef | 22445259PubMed | open url image1

[3]  Poynten IM, Stein AN, Conway EL, Prestage G, Regan DG, Jin F, Hocking J. Poynten IM, Stein AN, Conway EL, Prestage G, Regan DG, Jin F, Hocking J. Geographical clustering of anal cancer incidence in Australia. Sex Health 2012; 9 509–12.
Geographical clustering of anal cancer incidence in Australia.CrossRef | open url image1

[4]  Jin F, et al Trends in anal cancer in Australia, 1982–2005. Vaccine 2011; 29 2322–7.
Trends in anal cancer in Australia, 1982–2005.CrossRef | open url image1

[5]  Pandey P. Anal anatomy and normal histology. Sex Health 2012; 9 513–16. open url image1

[6]  Heywood W, Smith AMA. Anal sex practices in heterosexual and male homosexual populations: a review of population-based data. Sex Health 2012; 9 517–26. open url image1

[7]  Machalek DA, Grulich AE, Jin F, Templeton DA, Poynten IM. The epidemiology and natural history of anal human papillomavirus infection in men who have sex with men. Sex Health 2012; 9 527–37. open url image1

[8]  Nyitray AG. The epidemiology of anal human papillomavirus infection among women and men having sex with women. Sex Health 2012; 9 538–46.
The epidemiology of anal human papillomavirus infection among women and men having sex with women.CrossRef | open url image1

[9]  Coutlée F, de Pokomandy A, Franco EL. Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. Sex Health 2012; 9 547–55. open url image1

[10]  Roberts JM, Ekman D. The reporting of anal cytology and histology samples: establishing terminology and criteria. Sex Health 2012; 9 562–67. open url image1

[11]  Roberts JM, Thurloe JK. Comparison of performance of anal cytology and cervical cytology as screening tests. Sex Health 2012; 9 568–73.
Comparison of performance of anal cytology and cervical cytology as screening tests.CrossRef | open url image1

[12]  Darragh TM, Winkler B. Screening for anal neoplasia: anal cytology – sampling, processing, and reporting. Sex Health 2012; 9 556–61.
Screening for anal neoplasia: anal cytology – sampling, processing, and reporting.CrossRef | open url image1

[13]  Hillman RJ, van Leeuwen MT, Vajdic CM, McHugh L, Prestage GP, Botes LP. Hillman RJ, van Leeuwen MT, Vajdic CM, McHugh L, Prestage GP, Botes LP. Prevalence and predictors of high-grade anal intraepithelial neoplasia in a community-based sample of homosexual men. Sex Health 2012; 9 574–79. open url image1

[14]  Palefsky JM. Practising high-resolution anoscopy. Sex Health 2012; 9 580–86. open url image1

[15]  Fox PA. Treatment options for anal intraepithelial neoplasia and evidence for their effectiveness. Sex Health 2012; 9 587–92.
Treatment options for anal intraepithelial neoplasia and evidence for their effectiveness.CrossRef | open url image1

[16]  Szmulowicz UM, Wu JS. Squamous cell carcinoma of the anal canal: a review of the aetiology, presentation, staging, prognosis and methods available for treatment. Sex Health 2012; 9 593–609. open url image1

[17]  Howard K. The cost-effectiveness of screening for anal cancer in men who have sex with men: a systematic review. Sex Health 2012; 9 610–19.
The cost-effectiveness of screening for anal cancer in men who have sex with men: a systematic review.CrossRef | open url image1

[18]  Landstra JMB, Ciarrochi J, Deane FP. Psychosocial aspects of anal cancer screening: a review and recommendations. Sex Health 2012; 9 620–27. open url image1

[19]  Palefsky JM, et al HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365 1576–85.
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.CrossRef | open url image1

[20]  Donovan B, et al Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11 39–44.
Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.CrossRef | open url image1

[21]  Read TR, et al The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87 544–7.
The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.CrossRef | open url image1

[22]  Simatherai D, et al What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 2009; 85 148–9.
What men who have sex with men think about the human papillomavirus vaccine.CrossRef | open url image1

[23]  Conly JM, Shafran S. Targeted versus universal vaccination against hepatitis B: a paradigm shift. Can J Infect Dis Med Microbiol 1993; 4 171–2. open url image1

[24]  Department of Health and Ageing (DoHA). Positive recommendations on pharmaceutical benefits scheme – Pharmaceutical Benefits Advisory Committee (PBAC) in November 2011. Canberra: DoHA; 2012. Available online at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-nov11-positive [verified July 2012].

[25]  Grulich AE, et al Cancers attributable to human papillomavirus infection. Sex Health 2010; 7 244–52.
Cancers attributable to human papillomavirus infection.CrossRef | open url image1

[26]  Grulich AE, Hillman R, Brotherton JML, Fairley CK, et al Time for a strategic research response. Sex Health 2012; 9 628–631. open url image1


Full Text PDF (172.8 KB) Export Citation